Acne and hidradenitis suppurativa (HS) are chronic inflammatory skin conditions that significantly impact patients' quality of life. In the June issue of the Journal, we highlight the challenges in treating acne in skin of color (SOC) patients. Recent studies focusing on trifarotene, a selective retinoic acid receptor gamma agonist, demonstrated significant improvements in acne severity and postinflammatory hyperpigmentation in SOC patients. We will also delve into the early and aggressive treatment of HS and highlight a link between HS and increased cardiovascular risk. These insights demand a paradigm shift toward a more proactive and holistic management of HS, integrating skin and systemic health considerations to enhance patient outcomes significantly.
Keywords: acne; cardiovascular risk; comorbidity; hidradenitis suppurativa; skin of color (SOC); treatment; trifarotene.
© 2024 the International Society of Dermatology.